Tuğba Başoğlu: ESMO Open Article on Prognostic Role of NRG1 Variants in EGFR+ NSCLC
Tuğba Başoğlu, Associate Professor and Medical Oncologist at Kartal Dr. Lutfi Kirdar City Hospital, shared a post on X about a paper by E. Vita et al. published in ESMO Open:
“New data in ESMO Open:
In EGFR+ NSCLC treated with 1L osimertinib, concurrent NRG1 variants of uncertain significance (VUS) are an independent poor prognostic factor.
- PFS: 26.1 vs 12.1 mo
- OS: 34.1 vs 20.5 mo.”
Title: Network analysis of NRG1 variants of uncertain significance (VUSes) in advanced non-small-cell lung cancer and their prognostic role in EGFR-mutant patients treated with first-line osimertinib
Authors: E. Vita, A. Scala, A. Vitale, L. Mastrantoni, J. Evangelista, F. D’Auria, A. Stefani, F. Monaca, J. Russo, G. Horn, P. Troisi, A. Cosmai, S. Polidori, M. Di Salvatore, E. De Paolis, A. Minucci, C. Nero, R. Trisolini, A. Cancellieri, G. Scambia, G. Tortora, E. Bria
You can read the Full Article in ESMO Open.
More posts featuring Tuğba Başoğlu.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023